REDW Stock Overview
Engages in the development of ophthalmic drugs for medical needs in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Redwood Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr3.47 |
| 52 Week High | kr43.40 |
| 52 Week Low | kr0.51 |
| Beta | 0.45 |
| 11 Month Change | 233.65% |
| 3 Month Change | 153.28% |
| 1 Year Change | -91.08% |
| 33 Year Change | -99.47% |
| 5 Year Change | -99.50% |
| Change since IPO | -99.45% |
Recent News & Updates
Shareholder Returns
| REDW | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 347.2% | -1.5% | -3.4% |
| 1Y | -91.1% | 79.2% | 14.3% |
Return vs Industry: REDW underperformed the Swedish Pharmaceuticals industry which returned 79% over the past year.
Return vs Market: REDW underperformed the Swedish Market which returned 13.9% over the past year.
Price Volatility
| REDW volatility | |
|---|---|
| REDW Average Weekly Movement | 53.2% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.7% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: REDW's share price has been volatile over the past 3 months.
Volatility Over Time: REDW's weekly volatility has increased from 31% to 53% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1 | MV Vidaeus | www.redwoodpharma.se |
Redwood Pharma AB engages in the development of ophthalmic drugs for medical needs in Sweden. Its lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women; and RP501, a next generation smart hydrogel medical device for the treatment of mild dry eye. The company was founded in 2012 and is headquartered in Stockholm, Sweden.
Redwood Pharma AB Fundamentals Summary
| REDW fundamental statistics | |
|---|---|
| Market cap | kr9.21m |
| Earnings (TTM) | -kr13.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs REDW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REDW income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr13.60m |
| Earnings | -kr13.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did REDW perform over the long term?
See historical performance and comparison